Antimalarials inhibit human erythrocyte membrane acetylcholinesterase

Drug and Chemical Toxicology

Volumn 28, Issue 4, 2005, Pages 467-482

  Katewa, Subhash D ^a,b   Katyare, Surendra S ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Acetylcholinesterase; Antimalarials; Chloroquine; Primaquine; Quinine

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ANTIMALARIAL AGENT; CHLOROQUINE; PRIMAQUINE; QUININE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINESTERASE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; ERYTHROCYTE; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; NEUROPROTECTION; NEUROTOXICITY;

ACETYLCHOLINESTERASE; ADULT; ANTIMALARIALS; CHLOROQUINE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE MEMBRANE; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; PRIMAQUINE; QUININE;

CINCHONA PUBESCENS;

EID: 27644550734     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540500262912     Document Type: Article

References (30)

1. Aisen, P. S. (2002). Anti-inflammatory agents in Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2(5):405-409.
2. Aisen, P. S., Marin, D. B., Brickman, A. M., Santoro, J., Fusco, M. (2001). Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 15(2):96-101.
3. Citron, M. (2004). Strategies for disease modification in Alzheimer's disease. Nat. Rev., Neurosci. 5:677-685.
4. Dave, K. R., Syal, A. R., Katyare, S. S. (2000). Tissue cholinesterases. A comparative study of their kinetic properties. Z. Naturforsch. 55:100-108.
5. Dawson, L. J., Caulfield, V. L., Stanbury, J. B., Field, A. E., Christmas, S. E., Smith, P. M. (2005). Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology, 44(4):449-455.
6. Deepalakshmi, P. D., Parasakthy, K., Shanti, S., Devrajan, N. S. (1994). Effect of chloroquine on rat liver mitochondria. Indian J. Exp. Biol. 32:797-802.
7. Dixon, M., Webb, E. C. (1979). In: Dixon, M., Webb, E. C., Thorne, C. Jr., Tipton, K. F., eds. Enzymes. 3rd ed. London: Longman.
8. Ellman, G. L., Courtny, K. D., Anders, V., Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:88-95.
9. Farias, G. G., Godoy, J. A., Vazquez, M. C., Adani, R., Meshulam, H., Avila, J., Amitai, G., Inestrosa, N. C. (2005). The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 18:176-183.
10. Hanahan, D. J., Ekholm, J. F. (1978). The expression of optimum ATPase activities in human erythrocytes, a comparison of different lytic procedures. Arch. Biochem. Biophys. 187:170-179.
11. Inglis, F. (2002). The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract., Suppl. 127:45-63.
12. Int'Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M., Stricker, B. H. (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 645:1515-1521.
13. Jann, M. W., Shirley, K. L., Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41:719-739.
14. Jarzyna, R., Lenarcik, E., Bryla, J. (1997). Chloroquine is a potent inhibitor of glutamate dehydrogenase in liver and kidney-cortex of rabbit. Pharmacol. Res. 35(1):79-84.
15. Lim, L. Y., Go, M. L. (1985). The anticholinesterase activity of mefloquine. Clin. Exp. Pharmacol. Physiol. 12(5):527-531.
16. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951). Protein measurement with folin-phenol reagent. J. Biol. Chem. 193:265-272.
17. Luo, C., Saxena, A., Ashani, Y., Leader, H., Radic, Z., Taylor, P., Doctor, B. P. (1999). Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime. Chem.-Biol. Interact. 119-120:129-135.
18. (1998). Markesbery, W. R., ed. Neuropathology of Dementing Disorder. London: Arnold.
19. Masson, P., Froment, M., Bartels, F. C., Lockridge, O. (1996). Asp 70 in the peripheral anionic site of human butyrylcholinesterase. Eur. J. Biochem. 235:36-48.
20. Massoulie, J., Pezzeminti, L., Bon, S., Krejci, E., Vallette, F. (1993). Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41:31-91.
21. Mc Geer, E. G., Mc Geer, P. L. (1997). The role of the immune system in neurodegenerative disorders. Mov. Disord. 12:855-858.
22. Millerd, C. B., Lockridge, O., Broomfield, C. A. (1998). Organophosphorous acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in somanase. Biochemistry 37:237-247.
23. 42 induction by NSAIDs R-enantiomers. J. Neurochem. 83:1009-1012.
24. Saxena, A., Redman, A. M. G., Jiang, X., Lockridge, O., Doctor, B. P. (1997). Differences in the active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 36:14642-14651.
25. Scult, K. R., Gilman, A. L. (1997). The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leuk. Lymphoma 24:201-210.
26. Taylor, P. (2001). Anticholinesterase agents. In: Gilmann, A. G., Rall, T. W., Nies, A. S., Taylor, P., eds. The Pharmacological Basis of Therapeutics. 10th ed. New York: Pergamon Press, pp. 175-191.
27. Tracy, J. W., Leslie, T. W. Jr. (2001). Drugs used in the chemotherapy of protozoal infections-malaria. In: Gilmann, A. G., Rall, T. W., Nies, A. S., Taylor, P., eds. The Pharmacological Basis of Therapeutics. 10th ed. New York: Pergamon Press, pp. 1069-1109.
28. 42 independently of cyclooxygenase activity. Nature 414:212-216.
29. Yasojima, K, Schwab, C., Mc Geer, E. G., Mc Geer, P. L. (1999). Up-regulated production and activation of the compliment system in Alzheimer's disease brain. Am. J. Pathol. 154:927-936.
30. 42 by inhibiting Rho. Science 302:1215-1217.